当前位置: X-MOL 学术ACS Med. Chem. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of VU6015929: A Selective Discoidin Domain Receptor 1/2 (DDR1/2) Inhibitor to Explore the Role of DDR1 in Antifibrotic Therapy.
ACS Medicinal Chemistry Letters ( IF 3.5 ) Pub Date : 2019-11-25 , DOI: 10.1021/acsmedchemlett.9b00382
Daniel E Jeffries 1 , Corina M Borza 2 , Anna L Blobaum 3, 4 , Ambra Pozzi 2, 5 , Craig W Lindsley 1, 3, 4
Affiliation  

Herein, we report the discovery of a potent and selective dual DDR1/2 inhibitor, 7e (VU6015929), displaying low cytotoxicity, good kinome selectivity, and possessing an acceptable in vitro DMPK profile with good rodent in vivo pharmacokinetics. VU6015929 potently blocks collagen-induced DDR1 activation and collagen-IV production, suggesting DDR1 inhibition as an exciting target for antifibrotic therapy.

中文翻译:


发现 VU6015929:一种选择性盘状蛋白结构域受体 1/2 (DDR1/2) 抑制剂,用于探索 DDR1 在抗纤维化治疗中的作用。



在此,我们报道了一种有效的选择性双 DDR1/2 抑制剂 7e (VU6015929) 的发现,该抑制剂显示出低细胞毒性、良好的激酶组选择性,并具有可接受的体外 DMPK 谱和良好的啮齿动物体内药代动力学。VU6015929 有效阻断胶原蛋白诱导的 DDR1 活化和胶原蛋白 IV 的产生,表明 DDR1 抑制是抗纤维化治疗的令人兴奋的靶点。
更新日期:2019-12-06
down
wechat
bug